| Ingrezza (valbenazine) / Neurocrine |
NCT05157100: Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia |
|
|
| Completed | 4 | 20 | US | Ingrezza Pill | The Orthopedic Foundation | Cervical Dystonia | 09/23 | 09/23 | | |
NCT05859698: Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia |
|
|
| Active, not recruiting | 4 | 59 | US | Valbenazine, NBI-98854 | Neurocrine Biosciences | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 01/25 | 01/25 | | |
TD-AIDD, NCT06107829: Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities |
|
|
| Withdrawn | 4 | 25 | US | Valbenazine Oral Capsule, Ingrezza | Stephen Ruedrich, Neurocrine Biosciences | Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities | 01/27 | 02/27 | | |
2021-003714-39: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia |
|
|
| Not yet recruiting | 3 | 400 | Europe | Valbenazine, NBI-98854, Capsule | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
NCT04400331: Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
|
|
| Active, not recruiting | 3 | 154 | Canada, US | Valbenazine, NBI-98854 | Neurocrine Biosciences, Huntington Study Group | Chorea, Huntington | 03/26 | 03/26 | | |
NCT05206513: Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy |
|
|
| Recruiting | 3 | 80 | Europe, US, RoW | Placebo, Valbenazine, NBI-98854 | Neurocrine Biosciences | Dyskinesia, Cerebral Palsy | 06/25 | 01/26 | | |
NCT06312189: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada |
|
|
| Enrolling by invitation | 3 | 7 | Canada | Valbenazine, NBI-98854 | Neurocrine Biosciences | Chorea, Huntington | 04/26 | 04/26 | | |
NCT05110157 / 2021-003714-39: Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine As Adjunctive Treatment for Schizophrenia |
|
|
| Active, not recruiting | 3 | 442 | Europe, US, RoW | Placebo, Valbenazine, NBI-98854 | Neurocrine Biosciences, Neurocrine Biosciences, Inc. | Schizophrenia | 03/25 | 03/25 | | |
NCT05654870: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia |
|
|
| Terminated | 3 | 8 | US | Valbenazine, NBI-98854, Placebo | Neurocrine Biosciences | Schizophrenia | 11/23 | 11/23 | | |
NCT06771323: Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia |
|
|
| Not yet recruiting | 2 | 20 | US | Valbenazine, Placebo | Virginia Commonwealth University, Neurocrine Biosciences | Cervical Dystonia | 01/26 | 01/26 | | |
NCT05207085: Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults |
|
|
| Recruiting | 2 | 20 | US | Valbenazine Oral Capsule, Ingrezza, Placebo Oral capsule | Yale University, Neurocrine Biosciences | Trichotillomania (Hair-Pulling Disorder) | 10/25 | 10/26 | | |
NCT05053321: Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine |
|
|
| Recruiting | 1 | 15 | US | Valbenazine | Yale University, Neurocrine Biosciences | Tardive Dyskinesia | 10/25 | 10/25 | | |
| tetrabenazine / Generic mfg. |
NCT02509793: A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) |
|
|
| Recruiting | 4 | 20 | US | Tetrabenazine, Xenazine | William Ondo, MD, H. Lundbeck A/S | Huntington's Disease | 07/23 | 07/23 | | |
2011-004211-23: Etude d’efficacité et d’acceptabilité de la Tétrabénazine dans le syndrome tardif aux neuroleptiques |
|
|
| Not yet recruiting | 3 | 54 | Europe | XENAZINE, Buccal tablet, XENAZINE | CHU Amiens, EUSA Pharma | syndrome tardif aux neuroleptiques, syndrome tardif aux neuroleptiques, Diseases [C] - Nervous System Diseases [C10] | | | | |
2009-011594-33: A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia |
|
|
| Ongoing | 3 | 60 | Europe | Risperidone, Tetrabenazine, Risperdal, Risperdal | LWL University Hospital Bochum, Ruhr-University Bochum | Schizophrenia | | | | |
TBZ, NCT00642057: Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements |
|
|
| No Longer Available | N/A | | NA | tetrabenazine | Joseph Jankovic | Hyperkinetic Movement Disorders | | | | |
| Austedo (deutetrabenazine) / Teva |
ChiCTR2300077341: Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Chorea Associated with Huntington’s Disease |
|
|
| Not yet recruiting | 4 | 50 | | None | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Enterprise self-funded | Chorea Associated with Huntington’s Disease | | | | |
| Terminated | 3 | 44 | Europe, US, RoW | TEV-50717, Deutetrabenazine, SD-809 | Teva Branded Pharmaceutical Products R&D, Inc. | Cerebral Palsy, Dyskinetic | 02/23 | 02/23 | | |
NCT04713982: Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease |
|
|
| Recruiting | 2/3 | 30 | US | Deutetrabenazine, Austedo | Vanderbilt University Medical Center, Teva Branded Pharmaceutical Products R&D, Inc. | Huntington Disease | 08/25 | 04/26 | | |
AUDYT, NCT04173260: An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia |
|
|
| Completed | 1/2 | 15 | US | Deutetrabenazine 6 MG | University of Pennsylvania, Teva Branded Pharmaceutical Products R&D, Inc. | Dystonia, Primary | 03/24 | 08/24 | | |
NCT04301726: Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD |
|
|
| Not yet recruiting | 1 | 48 | NA | Deutetrabenazine Oral Tablet [Austedo], Austedo, Placebo oral tablet, Placebo | Fundacion Huntington Puerto Rico | Huntington Disease | 04/22 | 12/22 | | |
ChiCTR2300076925: An Open-Label, Single Dose Trial to Characterize the Pharmacokinetics of Deutetrabenazine and its Active Metabolites in Healthy Chinese Participants After a Single Dose of a 12-mg AUSTEDO® Tablet |
|
|
| Recruiting | 1 | 20 | | On day 1 (visit 2), healthy participants will be administered a 12-mg tablet of TEV-50717 under fed conditions. | West China Hospital of Sichuan University; Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Healthy Chinese Participants | | | | |
NCT04071639: Symptomatic Therapy for Patients With Huntington's Disease |
|
|
| Recruiting | 1 | 60 | RoW | Haloperidol 2Mg Tab, Haloperidol Tables, H31021234, Risperidone 1Mg Tab, Risperidone, H20010309, Zoloft 50Mg Tablet, Sertraline Hydrochloride Tablets, H10980141, Idebenone, Idebenone,H10970363, Deutetrabenazine Oral Tablet [Austedo], Deutetrabenazine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Huntington Disease | 12/24 | 12/24 | | |
| bevantolol (SOM3355) / SOM Biotech |
2021-003453-28: Phase IIb study assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. Estudio de Fase IIb para evaluar la eficacia y la seguridad de dos dosis de SOM3355 en pacientes con Enfermedad de Huntington con movimientos coreicos. |
|
|
| Not yet recruiting | 2 | 129 | Europe | SOM3355 (bevantolol hydrochloride), SOM3355, Capsule, Calvan (bevantolol hydrochloride) | SOM Innovation Biotech SA (SOM Biotech), SOM Innovation Biotech S.A., SOM Innovation Biotech SA (SOM Biotech) | Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Huntington’s Disease with choreic movements. Enfermedad de Huntington con movimientos coreicos., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 140 | Europe | SOM3355 capsules, Bevantolol hydrochloride, Placebo capsules | SOM Innovation Biotech SA, SOM Innovation Biotech SA (SOM Biotech) | Huntington Chorea | 06/24 | 07/24 | | |
| LY03015 / Luye Group |
NCT06731868: Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia |
|
|
| Not yet recruiting | 1/2 | 120 | RoW | LPM3770164 sustained release tablet 5 mg, LY03015, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg, LPM3770164 sustained release tablet simulant, placebo | Luye Pharma Group Ltd. | Tardive Dyskinesia (TD) | 10/25 | 10/25 | | |
NCT05238701: A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects |
|
|
| Completed | 1 | 104 | RoW | LPM3770164 sustained release tablet, LY03015, LPM3770164 sustained release tablet simulant, LY03015 simulant | Luye Pharma Group Ltd. | Huntington Disease, Tardive Dyskinesia | 11/23 | 11/23 | | |
NCT06216054: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects |
|
|
| Completed | 1 | 40 | RoW | LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant | Luye Pharma Group Ltd. | Tardive Dyskinesia, Huntington Disease | 07/24 | 07/24 | | |
NCT06474650: Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets |
|
|
| Completed | 1 | 16 | RoW | LPM3770164 sustained release tablet, LY03015 | Luye Pharma Group Ltd. | Huntington Disease, Tardive Dyskinesia | 09/24 | 09/24 | | |
| (+)-α-dihydrotetrabenazine (ADE 513) / Adeptio Pharma |
2022-000271-39: Evaluate the Efficacy, Safety and Tolerability of (+)-α-dihydrotetrabenazine for Treatment of Tardive Dyskinesia |
|
|
| Ongoing | 2 | 18 | RoW | (+)-α-dihydrotetrabenazine, Oral solution in bottle | Adeptio Pharmaceuticals Ltd, Adeptio Pharmaceuticals Ltd | Tardive dyskinesia, Tardive dyskinesia, Diseases [C] - Nervous System Diseases [C10] | | | | |
2022-001685-35: A trial to evaluate the efficacy, safety and tolerability of (+)-α-dihydrotetrabenazine for treatment of Tardive Dyskinesia |
|
|
| Not yet recruiting | 2 | 102 | RoW, Europe | ADE513, Oral solution | Adeptio Pharmaceuticals Limited, Adeptio Pharmaceuticals Limited | Tardive dyskinesia, Involuntary movements, Diseases [C] - Nervous System Diseases [C10] | | | | |
